Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Blood (2023) 142 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2023-174603

Published: 2023

Journal Articles

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Paola Guglielmelli, Fiorenza Irushani Vanderwert, Simone Romagnoli, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Laura Calabresi, Giulia Gentili, Giada Rotunno, Niccolò Bartalucci, Valentina Boldrini, Emanuela Sant'Antonio, Danilo Tarantino, Marco Pieraccioli, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 832–833.

https://doi.org/10.1182/blood-2022-156776

Published: 2022

Journal Articles

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

Oscar Borsani, Paul Bastard, Jérémie Rosain, Adrian Gervais, Emanuela Sant’Antonio, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Chiara Trotti, Silvia Catricalà, Virginia Valeria Ferretti, Luca Malcovati, Luca Arcaini, Jean-Laurent Casanova, Alessandro Borghesi, Elisa Rumi

Blood (2022) 139 (17): 2716–2720.

https://doi.org/10.1182/blood.2021014890

Published: 2022

Includes: Supplemental data

Journal Articles

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms

Oscar Borsani, Paul Bastard, Jérémie Rosain, Adrian Gervais, Emanuela Sant'Antonio, Daniele Vanni, Ilaria Carola Casetti, Daniela Pietra, Chiara Trotti, Virginia Valeria Ferretti, Luca Malcovati, Luca Arcaini, Alessandro Borghesi, Jean-Laurent Casanova, Elisa Rumi

Blood (2021) 138 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2021-150660

Published: 2021

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Elisa Rumi, MD, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Mario Cazzola, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1615.

https://doi.org/10.1182/blood.V126.23.1615.1615

Published: 2015

Journal Articles

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

Daniela Pietra, PhD, Elisa Rumi, MD, Chiara Milanesi, BS, Christian A Di Buduo, PhD, Marta Bellini, MD, Ilaria Carola Casetti, MD, Chiara Cavalloni, MD, Emanuela Sant'Antonio, Vittorio Abbonante, PhD, Maria C Renna, BS, Virginia Ferretti, PhD, Emanuela Boveri, MD, Alessandra Balduini, MD, Cristiana Pascutto, PhD, Mario Cazzola, MD

Blood (2014) 124 (21): 3215.

https://doi.org/10.1182/blood.V124.21.3215.3215

Published: 2014

Journal Articles

Clinical effect of driver mutations of JAK2 , CALR , or MPL in primary myelofibrosis

Blood (2014) 124 (7): 1062–1069.

https://doi.org/10.1182/blood-2014-05-578435

Published: 2014

Journal Articles

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic, Ilaria C. Casetti, Marta Bellini, Nicole C. C. Them, Chiara Cavalloni, Virginia V. Ferretti, Chiara Milanesi, Tiina Berg, Emanuela Sant’Antonio, Emanuela Boveri, Cristiana Pascutto, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2014) 123 (15): 2416–2419.

https://doi.org/10.1182/blood-2014-01-550434

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Blood (2014) 123 (10): 1544–1551.

https://doi.org/10.1182/blood-2013-11-539098

Published: 2014

Includes: Supplemental data

Journal Articles

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Blood (2013) 122 (21): LBA-1.

https://doi.org/10.1182/blood.V122.21.LBA-1.LBA-1

Published: 2013

Journal Articles

Whole Exome Sequencing Identifies Somatic Mutation Patterns Of Myeloid Cells In Patients With Myeloproliferative Neoplasms Treated With Allogeneic Bone Marrow Transplantation

Jelena D. Milosevic, Elisa Rumi, MD, Daniela Pietra, PhD, Klaudia Bagienski, M.Sc., Tiina Berg, Emanuela Sant'Antonio, MD, Anna Colombo, BsD, Francesco Ripamonti, MD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2013) 122 (21): 4101.

https://doi.org/10.1182/blood.V122.21.4101.4101

Published: 2013

Journal Articles

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL -mutated myeloproliferative neoplasms

Blood (2013) 121 (21): 4388–4395.

https://doi.org/10.1182/blood-2013-02-486050

Published: 2013

Includes: Supplemental data

NARROW

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

Clinical effect of driver mutations of JAK2 , CALR , or MPL in primary myelofibrosis

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms

Whole Exome Sequencing Identifies Somatic Mutation Patterns Of Myeloid Cells In Patients With Myeloproliferative Neoplasms Treated With Allogeneic Bone Marrow Transplantation

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL -mutated myeloproliferative neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only